148 related articles for article (PubMed ID: 25338126)
1. Microencapsulation of therapeutic bispecific antibodies producing cells: immunotherapeutic organoids for cancer management.
Saenz del Burgo L; Compte M; Aceves M; Hernández RM; Sanz L; Álvarez-Vallina L; Pedraz JL
J Drug Target; 2015 Feb; 23(2):170-9. PubMed ID: 25338126
[TBL] [Abstract][Full Text] [Related]
2. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
[TBL] [Abstract][Full Text] [Related]
3. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
Fournier P; Schirrmacher V
BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
[TBL] [Abstract][Full Text] [Related]
4. MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth.
Katayose Y; Kudo T; Suzuki M; Shinoda M; Saijyo S; Sakurai N; Saeki H; Fukuhara K; Imai K; Matsuno S
Cancer Res; 1996 Sep; 56(18):4205-12. PubMed ID: 8797593
[TBL] [Abstract][Full Text] [Related]
5. A novel bispecific antibody, S-Fab, induces potent cancer cell killing.
Li L; He P; Zhou C; Jing L; Dong B; Chen S; Zhang N; Liu Y; Miao J; Wang Z; Li Q
J Immunother; 2015; 38(9):350-6. PubMed ID: 26448579
[TBL] [Abstract][Full Text] [Related]
6. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
[TBL] [Abstract][Full Text] [Related]
7. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
[TBL] [Abstract][Full Text] [Related]
8. A mouse/human-chimeric bispecific antibody reactive with human carcinoembryonic antigen-expressing cells and human T-lymphocytes.
Kuwahara M; Kuroki M; Arakawa F; Senba T; Matsuoka Y; Hideshima T; Yamashita Y; Kanda H
Anticancer Res; 1996; 16(5A):2661-7. PubMed ID: 8917366
[TBL] [Abstract][Full Text] [Related]
9. The preparation of VEGFR1/CD3 bispecific antibody and its specific cytotoxicity against VEGFR1-positive breast cancer cells.
Tang P; Li L; Zhou Y; Shen CC; Kang YH; Yao YQ; Yi C; Gou LT; Yang JL
Biotechnol Appl Biochem; 2014; 61(4):376-84. PubMed ID: 24329807
[TBL] [Abstract][Full Text] [Related]
10. Alternative molecular formats and therapeutic applications for bispecific antibodies.
Spiess C; Zhai Q; Carter PJ
Mol Immunol; 2015 Oct; 67(2 Pt A):95-106. PubMed ID: 25637431
[TBL] [Abstract][Full Text] [Related]
11. Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts.
Aliperta R; Cartellieri M; Feldmann A; Arndt C; Koristka S; Michalk I; von Bonin M; Ehninger A; Bachmann J; Ehninger G; Bornhäuser M; Bachmann MP
Blood Cancer J; 2015 Sep; 5(9):e348. PubMed ID: 26383821
[TBL] [Abstract][Full Text] [Related]
12. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
[TBL] [Abstract][Full Text] [Related]
13. Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein x anti-CD3 diabody.
Gao Y; Xiong D; Yang M; Liu H; Peng H; Shao X; Xu Y; Xu C; Fan D; Qin L; Yang C; Zhu Z
Leukemia; 2004 Mar; 18(3):513-20. PubMed ID: 14981526
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
[TBL] [Abstract][Full Text] [Related]
15. Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells.
Urbanska K; Lynn RC; Stashwick C; Thakur A; Lum LG; Powell DJ
J Transl Med; 2014 Dec; 12():347. PubMed ID: 25496493
[TBL] [Abstract][Full Text] [Related]
16. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
17. Tumor-antigen-binding bispecific antibodies for cancer treatment.
Weidle UH; Kontermann RE; Brinkmann U
Semin Oncol; 2014 Oct; 41(5):653-60. PubMed ID: 25440609
[TBL] [Abstract][Full Text] [Related]
18. Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent.
Asano R; Sone Y; Makabe K; Tsumoto K; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
Clin Cancer Res; 2006 Jul; 12(13):4036-42. PubMed ID: 16818703
[TBL] [Abstract][Full Text] [Related]
19. A novel recombinant bispecific single-chain antibody, bscWue-1 x CD3, induces T-cell-mediated cytotoxicity towards human multiple myeloma cells.
Hönemann D; Kufer P; Rimpler MM; Chatterjee M; Friedl S; Riecher F; Bommert K; Dörken B; Bargou RC
Leukemia; 2004 Mar; 18(3):636-44. PubMed ID: 14737072
[TBL] [Abstract][Full Text] [Related]
20. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody.
Csóka M; Strauss G; Debatin KM; Moldenhauer G
Leukemia; 1996 Nov; 10(11):1765-72. PubMed ID: 8892680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]